Asia
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
Todos Medical Ltd. announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ scores with amyloid PET imaging scores.
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
Companies from across Europe, Asia and around the globe share pipeline and business updates.
Part of the problem with developing Alzheimer’s drugs has also been that the disease is still not well understood. What is known is that problems with cellular functions and/or improperly functioning proteins cause brain cells, called neurons, to become damaged, leading to their decreased function and eventually death.
An immunotherapy specialist is leveraging the advantages of investing in a new Quantum bioprocessing pump from Watson-Marlow Fluid Technology Group (WMFTG).
Prestige BioPharma announced positive results from a Phase I clinical trial evaluating the pharmacokinetics, safety and immunogenicity of biosimilar candidate HD204 to Avastin.
Prestige BioPharma and Pharmapark LLC announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.
Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area.
PRESS RELEASES